Reading critical changes in neuroblastoma’s genetic messages
Dr Jodie Bojko at the University of Bristol hopes to understand how genetic instructions are altered in neuroblastoma, and how this impacts the cancer.
Establishing a new comprehensive blood test to monitor rhabdomyosarcoma in children
Dr Supriti Ghosh at The Institute of Cancer Research hopes to learn more about how to use tiny fragments of DNA from the blood to monitor rhabdomyosarcoma.
Blocking the activity of an essential protein to treat T-cell acute lymphoblastic leukaemia
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Creating innovative new treatments for childhood rhabdomyosarcoma by harnessing the body’s natural defence system
Dr Matthew Blunt aims to create and test immunotherapy treatments for rhabdomyosarcoma that are safer and more effective than chemotherapy.
Studying immune cells to help develop new treatments for babies with leukaemia
Dr Samanta Mariani and her team want to understand more about the role immune cells play to help develop new ways to treat leukaemia in babies.
Looking for early signs on brain MRIs that can predict whether young people with ependymoma will go on to experience cognitive problems
Professor Shivaram Avula will identify markers in the brains of young people with brain tumours that will help predict the development of long-term side effects like learning and memory problems.
Targeting a protein to treat acute myeloid leukaemia in children
Dr Karen Keeshan is researching to see if removing or blocking a specific protein involved in acute myeloid leukaemia can help make it easier to treat.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.